Emily Woodworth, SVP, Global Controller, and CAO, has demonstrated a clear selling bias in her transactions involving Boston Scientific (BSX), with $2.1 million in total sales compared to $527,398 in purchases across 31 filings. Her recent activity has been exclusively focused on sales, with three transactions in early 2026, including a $28,588 disposition on March 1 and two earlier sales totaling $43,269 on February 16 and February 14. These follow a more substantial divestment pattern in early 2025, including a $999,872 sale on February 28 and a $750,465 transaction on March 3. While Woodworth has periodically acquired shares through derivative transactions—such as a $36,845 purchase on March 1, 2025, and smaller acquisitions in February 2025—the overall trend skews toward reducing her position. The absence of recent buys and the continuation of sales suggest a deliberate shift away from accumulating BSX holdings, though the transactions remain within the scope of routine executive trading activity. The filings indicate no open market purchases in 2026, reinforcing the directional trend toward liquidation rather than accumulation.
AI-assisted summary